| Date | Filer | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Aug 21, 2026 |
Director, Interim Chief Executive
Trans History: 14
|
Director, Interim Chief Executive | Form 4 | Open market or private purchase of non-derivative or derivative security | 4,000 | $1.22 | 4,000 |
| Aug 05, 2026 |
Principal Accounting Officer
Trans History: 18
|
Principal Accounting Officer | Form 3 | Initial Statement of Beneficial Ownership of Securities | 5,000 | -- | -- |
| Aug 05, 2026 |
General Counsel
Trans History: 14
|
General Counsel | Form 3 | Initial Statement of Beneficial Ownership of Securities | 15,000 | -- | -- |
| Aug 05, 2026 |
Chief Scientific Officer
Trans History: 3
|
Chief Scientific Officer | Form 3 | Initial Statement of Beneficial Ownership of Securities | 54,000 | -- | -- |
| Aug 05, 2026 |
Chief Operating Officer
Trans History: 32
|
Chief Operating Officer | Form 3 | Initial Statement of Beneficial Ownership of Securities | 15,000 | -- | -- |
| Aug 03, 2026 |
Principal Accounting Officer
Trans History: 18
|
Principal Accounting Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 5,000 | -- | 5,000 |
| Aug 03, 2026 |
General Counsel
Trans History: 14
|
General Counsel | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 15,000 | -- | 15,000 |
| Aug 03, 2026 |
Chief Scientific Officer
Trans History: 3
|
Chief Scientific Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 54,000 | -- | 54,000 |
| Aug 03, 2026 |
Chief Operating Officer
Trans History: 32
|
Chief Operating Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 15,000 | -- | 15,000 |
| Jul 30, 2026 |
Chief Scientific Officer
Trans History: 3
|
Chief Scientific Officer | Form 3 | Initial Statement of Beneficial Ownership of Securities | -- | -- | 63 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.